Eric P Raffin1, Kristina L Penniston2, Jodi A Antonelli3, Davis P Viprakasit4, Timothy D Averch5, Vincent G Bird6, Ben H Chew7, Sri Sivalingam8, Roger L Sur9, Stephen Y Nakada2, Vernon M Pais10. 1. Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire. Electronic address: eric.p.raffin@hitchcock.org. 2. University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 3. University of Texas Southwestern Medical Center, Dallas, Texas. 4. University of North Carolina School of Medicine, Chapel Hill, North Carolina. 5. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 6. University of Florida College of Medicine, Gainesville, Florida. 7. Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. 8. Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. 9. University of California-San Diego School of Medicine, San Diego, California. 10. Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
Abstract
PURPOSE: To our knowledge it is unknown whether the benefits of medical management of urolithiasis outweigh the potential side effects of the medications used, including potassium citrate and thiazide diuretics. Therefore, we evaluated the relationship between potassium citrate or thiazides and overall stone related health related quality of life. MATERIALS AND METHODS: Cross-sectional data were obtained on stone forming enrollees in the North American Stone Quality of Life Consortium. We used the WISQOL (Wisconsin Stone Quality of Life) questionnaire to compare health related quality of life between patients treated and not treated with potassium citrate or thiazide type diuretics. Additionally, the likelihood of gastrointestinal complaints was compared between those prescribed and not prescribed potassium citrate. The likelihood of fatigue and sexual complaints was also compared in those prescribed and not prescribed thiazides. RESULTS: Of the 1,511 subjects, including 787 males and 724 females, 279 were on potassium citrate and 238 were on thiazides at study enrollment. Patients prescribed potassium citrate had higher health related quality of life in each domain vs those not prescribed potassium citrate (p <0.001). Patients prescribed thiazides had higher health related quality of life in each domain compared to those not prescribed thiazide (all p <0.01). Those prescribed potassium citrate were less likely than those not prescribed potassium citrate to report nausea, stomach upset or cramps (OR 0.57, p <0.001). Patients prescribed thiazides were less likely than those not prescribed thiazides to report fatigue (OR 0.63, p = 0.004) or reduced sexual interest and/or activity (OR 0.64, p = 0.005). CONCLUSIONS: Among stone formers the use of potassium citrate and thiazides was associated with better health related quality of life across all WISQOL domains without an increased likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively. These findings may be useful when counseling patients regarding the initiation of potassium citrate or thiazides for medical management of nephrolithiasis.
PURPOSE: To our knowledge it is unknown whether the benefits of medical management of urolithiasis outweigh the potential side effects of the medications used, including potassium citrate and thiazide diuretics. Therefore, we evaluated the relationship between potassium citrate or thiazides and overall stone related health related quality of life. MATERIALS AND METHODS: Cross-sectional data were obtained on stone forming enrollees in the North American Stone Quality of Life Consortium. We used the WISQOL (Wisconsin Stone Quality of Life) questionnaire to compare health related quality of life between patients treated and not treated with potassium citrate or thiazide type diuretics. Additionally, the likelihood of gastrointestinal complaints was compared between those prescribed and not prescribed potassium citrate. The likelihood of fatigue and sexual complaints was also compared in those prescribed and not prescribed thiazides. RESULTS: Of the 1,511 subjects, including 787 males and 724 females, 279 were on potassium citrate and 238 were on thiazides at study enrollment. Patients prescribed potassium citrate had higher health related quality of life in each domain vs those not prescribed potassium citrate (p <0.001). Patients prescribed thiazides had higher health related quality of life in each domain compared to those not prescribed thiazide (all p <0.01). Those prescribed potassium citrate were less likely than those not prescribed potassium citrate to report nausea, stomach upset or cramps (OR 0.57, p <0.001). Patients prescribed thiazides were less likely than those not prescribed thiazides to report fatigue (OR 0.63, p = 0.004) or reduced sexual interest and/or activity (OR 0.64, p = 0.005). CONCLUSIONS: Among stone formers the use of potassium citrate and thiazides was associated with better health related quality of life across all WISQOL domains without an increased likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively. These findings may be useful when counseling patients regarding the initiation of potassium citrate or thiazides for medical management of nephrolithiasis.
Authors: Flora Szeri; Stefan Lundkvist; Sylvia Donnelly; Udo F H Engelke; Kyu Rhee; Charlene J Williams; John P Sundberg; Ron A Wevers; Ryan E Tomlinson; Robert S Jansen; Koen van de Wetering Journal: PLoS Genet Date: 2020-07-08 Impact factor: 5.917